Trial · NCT03733145
Angiotensin II in General Anesthesia
NCT03733145, Phase 4, Completed, Wake Forest University Health Sciences; results first posted 2025-08-24
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Angiotensin II in General Anesthesia. Trials, record NCT03733145. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03733145
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Angiotensin II in General Anesthesia
- NCT number
- NCT03733145
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 32 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Hypertension
- Interventions
- Angiotensin II
- First posted
- 2018-11-07
- Last updated
- 2025-08-24
- Results first posted
- 2025-08-24
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Dose Required to Increase the Systolic Blood Pressure (SBP) | up to 1 hour | The median dose required to increase the SBP in these 3 cohorts with essential hypertension (ACE inhibitor, ARB, or those on another class of hypertensive agents) to within 5% of baseline or higher will be calculated. |
| Secondary | Median Serum Level of Bradykinin 1-8 | up to 1 hour | Median serum level of Bradykinin 1-8 |
| Secondary | Median Serum Level of Bradykinin 1-7 | Up to 1 hour | Median serum level of Bradykinin 1-7 |
| Secondary | Median Serum Level of Bradykinin 1-5 | Up to 1 hour | Median serum level of Bradykinin 1-5 |
| Secondary | Median Serum Level of Aldosterone | Up to 1 hour | Median serum level of Aldosterone |
| Secondary | Median Serum Level of Angiotensin I | Up to 1 hour | Median serum level of Angiotensin I |
| Secondary | Median Serum Level of Angiotensin II | up to 1 hour | Median serum level of Angiotensin II |
| Secondary | Median Serum Level of Angiotensin IV | Up to 1 hour | Median serum level of Angiotensin IV |
| Secondary | Median Serum Level of Angiotensin 1-7 | Up to 1 hour | Median serum level of Angiotensin 1-7 |
| Secondary | Median Serum Level of Angiotensin 1-5 | Up to 1 hour | Median serum level of Angiotensin 1-5 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Median Dose Required to Increase the Systolic Blood Pressure (SBP) | up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol ARB Arm: 2 patients did not reach the treatment goal in this group and were therefore excluded from primary outcome analysis Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | ng/kg/min | MEDIAN |
| SECONDARY | Median Serum Level of Bradykinin 1-8 | up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Bradykinin 1-7 | Up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Bradykinin 1-5 | Up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Aldosterone | Up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Angiotensin I | Up to 1 hour | ACE Inhibitor Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Angiotensin II | up to 1 hour | ACE Inhibitors Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Angiotensin IV | Up to 1 hour | ACE Inhibitors Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Angiotensin 1-7 | Up to 1 hour | ACE Inhibitors Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
| SECONDARY | Median Serum Level of Angiotensin 1-5 | Up to 1 hour | ACE Inhibitors Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol Other Classes of Antihypertensive Agents Arm: 2 patients did not experience hypotension and therefore did not receive the Ang II per protocol | pmol/L | MEDIAN |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 outcomesResults by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Dose Required to Increase the Systolic Blood Pressure (SBP) | Participants on ACE Inhibitors | 35 | Inter-Quartile Range 35 to 45 | ng/kg/min | |
| Median Dose Required to Increase the Systolic Blood Pressure (SBP) | Participants on ARBs | 43 | Inter-Quartile Range 31 to 54 | ng/kg/min | |
| Median Dose Required to Increase the Systolic Blood Pressure (SBP) | Other Classes of Antihypertensive Agents | 45 | Inter-Quartile Range 34 to 45 | ng/kg/min | |
| Median Serum Level of Bradykinin 1-8 | Participants on ACE Inhibitors | 127043 | Inter-Quartile Range 103938 to 180738 | pmol/L | |
| Median Serum Level of Bradykinin 1-8 | Participants on ARBs | 105405 | Inter-Quartile Range 71387 to 122527 | pmol/L | |
| Median Serum Level of Bradykinin 1-8 | Other Classes of Antihypertensive Agents | 101169 | Inter-Quartile Range 75851 to 130402 | pmol/L | |
| Median Serum Level of Bradykinin 1-7 | Participants on ACE Inhibitors | 24457 | Inter-Quartile Range 19026 to 35010 | pmol/L | |
| Median Serum Level of Bradykinin 1-7 | Participants on ARBs | 19335 | Inter-Quartile Range 11044 to 36966 | pmol/L | |
| Median Serum Level of Bradykinin 1-7 | Other Classes of Antihypertensive Agents | 17438 | Inter-Quartile Range 11906 to 25482 | pmol/L | |
| Median Serum Level of Bradykinin 1-5 | Participants on ACE Inhibitors | 2341 | Inter-Quartile Range 1483 to 4095 | pmol/L |
1 to 10 of 45Source ClinicalTrials.gov
See all 45 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants on ACE Inhibitors | 10 | |
| Overall Study | STARTED | Participants on ARBs | 11 | |
| Overall Study | STARTED | Other Classes of Antihypertensive Agents | 11 | |
| Overall Study | COMPLETED | Participants on ACE Inhibitors | 7 | |
| Overall Study | COMPLETED | Participants on ARBs | 8 | |
| Overall Study | COMPLETED | Other Classes of Antihypertensive Agents | 9 | |
| Overall Study | NOT COMPLETED | Participants on ACE Inhibitors | 3 | |
| Overall Study | NOT COMPLETED | Participants on ARBs | 3 | |
| Overall Study | NOT COMPLETED | Other Classes of Antihypertensive Agents | 2 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leg Swelling | Vascular disorders | Participants on ACE Inhibitors | 1 | 5 | |
| other | Leg Swelling | Vascular disorders | Participants on ARBs | 0 | 8 | |
| other | Leg Swelling | Vascular disorders | Other Classes of Antihypertensive Agents | 0 | 7 | |
| other | Blurred Vision | Eye disorders | Participants on ACE Inhibitors | 0 | 5 | |
| other | Blurred Vision | Eye disorders | Participants on ARBs | 1 | 8 | |
| other | Blurred Vision | Eye disorders | Other Classes of Antihypertensive Agents | 0 | 7 | |
| other | Pain | Musculoskeletal and connective tissue disorders | Participants on ACE Inhibitors | 0 | 5 | |
| other | Pain | Musculoskeletal and connective tissue disorders | Participants on ARBs | 1 | 8 | |
| other | Pain | Musculoskeletal and connective tissue disorders | Other Classes of Antihypertensive Agents | 0 | 7 | |
| other | Shortness of Breath | Respiratory, thoracic and mediastinal disorders | Participants on ACE Inhibitors | 0 | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants on ACE Inhibitors | 0 | 5 |
| Total, all-cause mortality | Participants on ARBs | 0 | 8 |
| Total, all-cause mortality | Other Classes of Antihypertensive Agents | 0 | 7 |
| Total, other adverse events | Participants on ACE Inhibitors | 1 | 5 |
| Total, other adverse events | Participants on ARBs | 2 | 8 |
| Total, other adverse events | Other Classes of Antihypertensive Agents | 0 | 7 |
| Total, serious adverse events | Participants on ACE Inhibitors | 0 | 5 |
| Total, serious adverse events | Participants on ARBs | 0 | 8 |
| Total, serious adverse events | Other Classes of Antihypertensive Agents | 0 | 7 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03733145
GET https://conductscience.org/api/trials/v1/NCT03733145/results?page=2